Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: A Children's Oncology Group study

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 742-756

  Gadd, Samantha ^a   Huff, Vicki ^b   Huang, Chiang Ching ^a   Cristy Ruteshouser, E ^b   Dome, Jeffrey S ^c   Grundy, Paul E ^d   Breslow, Norman ^e   Jennings, Lawrence ^a   Green, Daniel M ^f   Bruce Beckwith, J ^g   Perlman, Elizabeth J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CTNNB1 GENE; DNA METHYLATION; GENE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MESENCHYME; MESODERM; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; ONTOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WT1 GENE; WTX GENE;

EID: 84865245097     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12714     Document Type: Article

References (66)

1. Beckwith JB, Kiviat NB, and Bonadio JF (1990). Nephrogenic rests, nephro-blastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 10, 1-36.
2. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, and Jaenisch R (1993). WT-1 is required for early kidney development. Cell 74, 679-691.
3. Scharnhorst V, van der Eb AJ, and Jochemsen AG (2001). WT1 proteins: functions in growth and differentiation. Gene 273, 141-161.
4. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, and Fouser L (1991). Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437-447.
5. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, and Lewis WH (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60, 509-520.
6. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, and Bruns GA (1990). Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774-778.
7. Varanasi R, Bardeesy N, Ghahremani M, Petruzzi MJ, Nowak N, Adam MA, Grundy P, Shows TB, and Pelletier J (1994). Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 91, 3554-3558.
8. Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, et al. (1994). Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum Mutat 3, 212-222.
9. Huff V (1998). Wilms tumor genetics. Am J Med Genet 79, 260-267.
10. Maiti S, Alam R, Amos CI, and Huff V (2000). Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 60, 6288-6292.
11. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, and von Knebel DM (1999). Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59, 3880-3882.
12. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. (2007). Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 316, 1043-1046.
13. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, et al. (2007). An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315, 642-645.
14. Ruteshouser EC, Robinson SM, and Huff V (2008). Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47, 461-470.
15. Perotti D, Gamba B, Sardella M, Spreafico F, Terenziani M, Collini P, Pession A, Nantron M, Fossati-Bellani F, and Radice P (2008). Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 27, 4625-4632.
16. Fukuzawa R, Heathcott RW, More HE, and Reeve AE (2007). Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol 60, 1013-1016.
17. Uschkereit C, Perez N, de Torres C, Kuff M, Mora J, and Royer-Pokora B (2007). Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. J Med Genet 44, 393-396.
18. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, and Feinberg AP (1993). Relaxation of imprinted genes in human cancer. Nature 362, 747-749.
19. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, and Feinberg AP (1989). Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 44, 720-723.
20. Weksberg R, Shen DR, Fei YL, Song QL, and Squire J (1993). Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet 5, 143-150.
21. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, and Reeve AE (1993). Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362, 749-751.
22. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, Tohonen V, Hedborg F, Schofield P, Flam F, and Ekstrom TJ (1993). IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet 4, 94-97.
23. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, and Feinberg AP (1994). Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 7, 433-439. Erratum in Nat Genet 1994;8:203.
24. Chao LY, Huff V, Tomlinson G, Riccardi VM, Strong LC, and Saunders GF (1993). Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat Genet 3, 127-131.
25. Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar J, Strong L, Behringer RR, and Huff V (2011). Wt1 ablation and Igf2-up-regulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 121, 174-183.
26. Rahman N, Abidi F, Ford D, Arbour L, Rapley E, Tonin P, Barton D, Batcup G, Berry J, Cotter F, et al. (1998). Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1. Hum Genet 103, 547-556.
27. MacDonald JM, Douglass EC, Fisher R, Geiser CF, Krill CE, Strong LC, Virshup D, and Huff V (1998). Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 58, 1387-1390.
28. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, et al. (2005). Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23, 7312-7321.
29. Brunskill EW, Aronow BJ, Georgas K, Rumballe B, Valerius MT, Aronow J, Kaimal V, Jegga AG, Yu J, Grimmond S, et al. (2008). Atlas of gene expression in the developing kidney at microanatomic resolution. Dev Cell 15, 781-791.
30. Lin SA, Kolle G, Grimmond S, Zhou Q, Doust E, Little MH, Aronow BJ, Ricardo SD, Pera MF, Bertram JF, et al. (2010). Subfractionation of differentiating human embryonic stem cell populations allows the isolation of a mesodermal population enriched for intermediate mesoderm and putative renal progenitors. Stem Cells Dev 19, 1637-1648.
31. Huang CC, Gadd S, Breslow NB, Cutcliffe C, Sredni S, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, et al. (2009). Predicting relapse in favorable histology Wilms tumor using gene expression analysis. A report from the renal tumor committee of the Children's Oncology Group. Clin Cancer Res 15, 1770-1778.
32. Huang CC, Cutcliffe C, Coffin C, Sorensen PH, Beckwith JB, and Perlman EJ (2006). Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer 46, 728-738.
33. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
34. Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, Shamberger RC, Ruteshouser EC, and Huff V (2011). WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a Children's Oncology Group study. J Clin Oncol 29, 698-703.
35. Huff V, Jaffe N, Saunders GF, Strong LC, Villalba F, and Ruteshouser EC (1995). WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56, 84-90.
36. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, and Tycko B (2002). Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160, 2181-2190.
37. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, et al. (2006). Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 66, 6040-6049.
38. Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM, and Fung KM (2009). Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol 3, 147-155.
39. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ III, and Kim SJ (1994). Repression of the transforming growth factor-β 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 8, 595-602.
40. Singh G, Singh SK, Konig A, Reutlinger K, Nye MD, Adhikary T, Eilers M, Gress TM, Fernandez-Zapico ME, and Ellenrieder V (2010). Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-β switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 285, 27241-27250.
41. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, and Reeve AE (2009). Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 28, 1063-1075.
42. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, et al. (2004). CTNNB1 mutations and overexpres-sion of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165, 1943-1953.
43. Corbin M, de Reynies A, Rickman DS, Berrebi D, Boccon-Gibod L, Cohen-Gogo S, Fabre M, Jaubert F, Faussillon M, Yilmaz F, et al. (2009). WNT/ β-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer 48, 816-827.
44. Schwab K, Patterson LT, Aronow BJ, Luckas R, Liang HC, and Potter SS (2003). A catalogue of gene expression in the developing kidney. Kidney Int 64, 1588-1604.
45. Moore AW, McInnes L, Kreidberg J, Hastie ND, and Schedl A (1999). YAC complementation shows a requirement for Wt1 in the development of epi-cardium, adrenal gland and throughout nephrogenesis. Development 126, 1845-1857.
46. Miller-Hodges E and Hohenstein P (2012). WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol 226, 229-240.
47. Park JS, Valerius MT, and McMahon AP (2007). Wnt/β-catenin signaling regulates nephron induction during mouse kidney development. Development 134, 2533-2539.
48. Iglesias DM, Hueber PA, Chu L, Campbell R, Patenaude AM, Dziarmaga AJ, Quinlan J, Mohamed O, Dufort D, and Goodyer PR (2007). Canonical WNT signaling during kidney development. Am J Physiol Renal Physiol 293, F494-F500.
49. Schmidt-Ott KM, Masckauchan TN, Chen X, Hirsh BJ, Sarkar A, Yang J, Paragas N, Wallace VA, Dufort D, Pavlidis P, et al. (2007). β-Catenin/TCF/ Lef controls a differentiation-associated transcriptional program in renal epithelial progenitors. Development 134, 3177-3190.
50. Etheridge SL, Spencer GJ, Heath DJ, and Genever PG (2004). Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 22, 849-860.
51. Lindsley RC, Gill JG, Kyba M, Murphy TL, and Murphy KM (2006). Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. Development 133, 3787-3796.
52. Yun K, Molenaar AJ, Fiedler AM, Mark AJ, Eccles MR, Becroft DM, and Reeve AE (1993). Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney. Lab Invest 69, 603-615.
53. Schroeder WT, Chao LY, Dao DD, Strong LC, Pathak S, Riccardi V, Lewis WH, and Saunders GF (1987). Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet 40, 413-420.
54. Haruta M, Arai Y, Sugawara W, Watanabe N, Honda S, Ohshima J, Soejima H, Nakadate H, Okita H, Hata J, et al. (2008). Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 47, 712-727.
55. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R, and Royer-Pokora B (1997). Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA 94, 3972-3977.
56. Miyagawa K, Kent J, Moore A, Charlieu JP, Little MH, Williamson KA, Kelsey A, Brown KW, Hassam S, Briner J, et al. (1998). Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour [letter]. Nat Genet 18, 15-17.
57. Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y, Becroft DM, Beckwith JB, Perlman EJ, and Reeve AE (2004). Epigenetic differences between Wilms' tumours in white and East-Asian children. Lancet 363, 446-451.
58. Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, and Reeve AE (2004). Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 7, 125-137.
59. Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, et al. (2011). The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell 20, 583-596.
60. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, and Feinberg AP (2001). Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93, 1698-1703.
61. Cutcliff C, Kersey D, Huang CC, Hasan C, Walterhouse D, and Perlman EJ (2005). Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 11, 7986-7994.
62. Gadd S, Beezhold P, Jennings L, George D, Leuer K, Huang CC, Huff V, Tognon C, Sorensen PH, Triche T, et al. (in press). Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol.
63. Gadd S, Sredni ST, Huang CC, and Perlman EJ (2010). Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest 90, 724-738.
64. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Perlman E, Donaldson M, Grundy PE, et al. (2001). Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 19, 3719-3724.
65. Sredni S, Gadd S, Huang CC, Breslow N, Grundy P, Green DM, Dome J, Shamberger RC, Beckwith B, and Perlman EJ (2009). Subsets of very low risk Wilms tumors show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 15, 6800-6809.
66. Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, and Gessler M (2006). Target genes of the WNT/β-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 45, 565-574.